RecruitingPhase 1NCT04319848

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty

Safety and Efficacy of Tissue Engineered Endothelial Keratoplasty (TE-EK)


Sponsor

Singapore Eye Research Institute

Enrollment

30 participants

Start Date

Dec 1, 2017

Study Type

INTERVENTIONAL

Conditions

Summary

Assessment of safety and efficacy of tissue-engineered corneal endothelial graft material generated using cultured human corneal endothelial cells for tissue-engineered endothelial keratoplasty (TE-EK).


Eligibility

Min Age: 21 YearsMax Age: 80 Years

Inclusion Criteria3

  • Patients who have mild to moderate corneal endothelial decompensation or bullous keratopathy, but with minimal corneal stromal scarring resulting from a variety of conditions including:
  • Fuchs' endothelial dystrophy
  • Post-surgical corneal decompensation (irreversible) - all forms of pseudophakic or aphakic bullous keratopathy

Exclusion Criteria10

  • Severe forms or late stage presentation of corneal decompensation with severe corneal stromal scarring, unsuitable for TE-EK surgery as opposed to penetrating keratoplasty
  • Patients with complex anterior segment complications precluding a successful TE-EK procedure
  • Patients who have other forms of endothelial dystrophy, traumatic corneal decompensation, or post-inflammatory corneal decompensation
  • Post-laser iridotomy or glaucoma related corneal decompensation
  • Patients not keen to participate in the clinical trial
  • Patients who are below 21 years of age or above 80 years of age
  • Patients who are pregnant
  • Patients who are cognitively impaired
  • Patients who are prisoners
  • Patients who are allergic to antibiotics

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERTE-EK treatment group

Transplantation of tissue-engineered endothelial graft through DSAEK procedure.


Locations(1)

Singapore Eye Research Institute

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04319848


Related Trials